La Jolla Pharmaceutical
LJPC
LJPC was delisted on the 19th of August, 2022.
73 hedge funds and large institutions have $256M invested in La Jolla Pharmaceutical in 2016 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 7 closing their positions.
191% more call options, than puts
Call options by funds: $3.57M | Put options by funds: $1.22M
76% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 17
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
4% more funds holding
Funds holding: 70 → 73 (+3)
0.99% less ownership
Funds ownership: 88.49% → 87.5% (-0.99%)
23% less capital inflows, than outflows
Capital inflows: $24.1M | Capital outflows: $31.1M
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
+$11.4M |
| 2 |
Janus Henderson Investors US
Denver,
Colorado
|
+$2.13M |
| 3 |
Broadfin Capital
New York
|
+$2.08M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.69M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$904K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Visium Asset Management
New York
|
-$24.8M |
| 2 |
Avoro Capital Advisors
New York
|
-$2.54M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$616K |
| 4 |
Oxford Asset Management
Oxford,
United Kingdom
|
-$559K |
| 5 |
Millennium Management
New York
|
-$464K |
LJPC Hedge Fund Activity: Q2 2016 in Review
73 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical (LJPC) for Q2 2016, worth a combined $256M — down 24% from $337M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LJPC positions and 7 closed out — a net gain of 3 holders — while 30 added to existing stakes and 17 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $11.4M. The largest seller was Visium Asset Management, exiting entirely with an estimated $24.8M sold.
- 73 institutional investors held La Jolla Pharmaceutical (LJPC) as of Q2 2016, up from 70 in Q1 2016.
- Funds reported $256M of La Jolla Pharmaceutical stock for Q2 2016, down 24% quarter-over-quarter.
- 10 funds opened new La Jolla Pharmaceutical positions in Q2 2016 and 7 closed out, a net change of +3 holders.
- The largest La Jolla Pharmaceutical buyer in Q2 2016 was Perceptive Advisors, an estimated $11.4M added.
- The largest La Jolla Pharmaceutical seller in Q2 2016 was Visium Asset Management, an estimated $24.8M sold.
Based on aggregated 13F filings for Q2 2016.